Li et al. showed that telmisartan could downregulate ANP and BNP expression by inhibiting the NFAT signaling pathway (Li et al., 2017), which effectively inhibits cardiac hypertrophy. This evidence concerns the gene NPPB and cardiac hypertrophy.